Skip to content

ACUTA CAPITAL PARTNERS, LLC

Follow

13F filer, CIK 1582844, REDWOOD CITY, CA

ACUTA CAPITAL PARTNERS, LLC reported $131,607,387 across 35 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 68.93% of the portfolio.

Accepted , ingested 13F-HR 0001104659-26-127905

Period
2026-09-30
Reported value
$132M
Holdings
35
Top 10 weight
68.93%
New
12
Sold out
0

Largest buys vs the previous quarter

SecurityShares changeApprox. value
VOGXnew+213,186$4.86M
SLNnew+393,583$4.3M
IRDnew+514,110$2.49M
RVMDnew+8,237$1.69M
IRLAnew+52,918$1.64M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
STROreduced-244,961-$3.95M
AMLXreduced-105,159-$3.06M
ERASreduced-197,658-$2.9M
DSGNreduced-167,172-$2.1M
AVBPreduced-47,801-$1.45M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001104659-26-127905, largest first. % of portfolio is the value over $129,592,387, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PRAXPRAXIS PRECISION MEDICINES IQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 67,500 shares; 2025Q1: 87,141 shares; 2025Q2: 74,087 shares; 2025Q3: 49,751 shares; 2025Q4: 83,036 shares; 2026Q1: 84,901 shares; 2026Q2: 82,796 shares; 2026Q3: 84,193 shares 84,193$24.5M18.92%+1,397Timeline
WHWKWHITEHAWK THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,849,402 shares; 2025Q1: 3,410,402 shares; 2025Q2: 3,410,402 shares; 2025Q3: 3,410,402 shares; 2025Q4: 3,410,402 shares; 2026Q1: 3,410,402 shares; 2026Q2: 4,685,912 shares; 2026Q3: 4,685,912 shares 4,685,912$17.6M13.6%0Timeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 282,732 shares; 2026Q1: 441,831 shares; 2026Q2: 390,949 shares; 2026Q3: 409,529 shares 409,529$10.2M7.88%+18,580Timeline
FDMT4D MOLECULAR THERAPEUTICS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 507,801 shares; 2026Q3: 535,109 shares 535,109$7.66M5.91%+27,308Timeline
ARGXARGENX SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 6,910 shares; 2025Q1: 7,023 shares; 2025Q2: 6,702 shares; 2025Q3: 6,379 shares; 2025Q4: 4,851 shares; 2026Q1: 4,690 shares; 2026Q2: 4,705 shares; 2026Q3: 5,558 shares 5,558$5.33M4.11%+853Timeline
AVBPARRIVENT BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 218,694 shares; 2026Q3: 170,893 shares 170,893$5.17M3.99%-47,801Timeline
SRZNSURROZEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 170,000 shares; 2025Q2: 170,000 shares; 2025Q3: 178,415 shares; 2025Q4: 178,415 shares; 2026Q1: 172,847 shares; 2026Q2: 173,395 shares; 2026Q3: 152,541 shares 152,541$4.91M3.79%-20,854Timeline
VOGXVOGENX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 213,186 shares 213,186$4.86M3.75%newTimeline
DRUGBRIGHT MINDS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 69,124 shares; 2025Q1: 59,748 shares; 2025Q2: 48,474 shares; 2025Q3: 84,875 shares; 2025Q4: 84,477 shares; 2026Q1: 111,996 shares; 2026Q2: 92,745 shares; 2026Q3: 93,152 shares 93,152$4.64M3.58%+407Timeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,111,071 shares; 2025Q1: 1,219,724 shares; 2025Q2: 1,014,940 shares; 2025Q3: 1,165,206 shares; 2025Q4: 1,052,995 shares; 2026Q1: 592,108 shares; 2026Q2: 532,481 shares; 2026Q3: 574,543 shares 574,543$4.41M3.4%+42,062Timeline
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 393,583 shares 393,583$4.3M3.32%newTimeline
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 884,244 shares; 2025Q1: not reported; 2025Q2: 485,669 shares; 2025Q3: 454,827 shares; 2025Q4: 454,827 shares; 2026Q1: 439,464 shares; 2026Q2: 561,808 shares; 2026Q3: 691,843 shares 691,843$3.37M2.6%+130,035Timeline
AVLNAVALYN PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 115,000 shares; 2026Q3: 114,749 shares 114,749$3.27M2.52%-251Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 60,808 shares; 2026Q2: 186,308 shares; 2026Q3: 186,308 shares 186,308$2.86M2.2%0Timeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 59,280 shares; 2026Q1: 191,760 shares; 2026Q2: 215,652 shares; 2026Q3: 216,568 shares 216,568$2.53M1.96%+916Timeline
IRDOPUS GENETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 514,110 shares 514,110$2.49M1.92%newTimeline
NERVMINERVA NEUROSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 709,500 shares; 2026Q1: 709,500 shares; 2026Q2: 709,500 shares; 2026Q3: 729,500 shares 729,500$2.44M1.89%+20,000Timeline
LBRXLB PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 30,000 shares; 2025Q4: 30,000 shares; 2026Q1: 28,919 shares; 2026Q2: 28,919 shares; 2026Q3: 52,718 shares 52,718$2.02M1.56%+23,799Timeline
ARTVARTIVA BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 44,000 shares; 2025Q1: 45,456 shares; 2025Q2: 45,456 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 260,416 shares; 2026Q3: 260,416 shares 260,416$1.85M1.43%0Timeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 333,258 shares; 2025Q4: 333,258 shares; 2026Q1: 151,067 shares; 2026Q2: 168,115 shares; 2026Q3: 62,956 shares 62,956$1.83M1.41%-105,159Timeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 111,700 shares; 2025Q1: 66,662 shares; 2025Q2: 55,693 shares; 2025Q3: 8,411 shares; 2025Q4: 8,411 shares; 2026Q1: 26,069 shares; 2026Q2: not reported; 2026Q3: 8,237 shares 8,237$1.69M1.3%newTimeline
IRLAQUINCE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 52,918 shares 52,918$1.64M1.27%newTimeline
ROIVROIVANT SCIENCES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 41,535 shares 41,535$1.52M1.17%newTimeline
DSGNDESIGN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 150,906 shares; 2026Q1: 145,900 shares; 2026Q2: 282,564 shares; 2026Q3: 115,392 shares 115,392$1.45M1.12%-167,172Timeline
UTHRUNITED THERAPEUTICS CORP DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,296 shares; 2025Q4: 2,296 shares; 2026Q1: 2,224 shares; 2026Q2: 2,224 shares; 2026Q3: 2,240 shares 2,240$1.21M0.94%+16Timeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 63,095 shares; 2026Q3: 89,826 shares 89,826$1.21M0.93%+26,731Timeline
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 87,918 shares 87,918$1.18M0.91%newTimeline
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 354,575 shares; 2026Q2: 265,199 shares; 2026Q3: 67,541 shares 67,541$990K0.76%-197,658Timeline
ANTXAN2 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 142,051 shares 142,051$756K0.58%newTimeline
ADILADIAL PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 129,982 shares 129,982$521K0.4%newTimeline
STROSUTRO BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 67,451 shares; 2026Q1: 269,425 shares; 2026Q2: 270,251 shares; 2026Q3: 25,290 shares 25,290$407K0.31%-244,961Timeline
EQEQUILLIUM INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 183,000 shares 183,000$297K0.23%newTimeline
CMPXCOMPASS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 840,090 shares; 2025Q4: 1,093,300 shares; 2026Q1: 849,076 shares; 2026Q2: 595,213 shares; 2026Q3: 251,001 shares 251,001$261K0.2%-344,212Timeline
STOKSTOKE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 5,771 shares 5,771$150K0.12%newTimeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
ACADACADIA PHARMACEUTICALS INC COMcall1,000$2.02Mnew

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-26-127905 base2026-11-16